$XNCR is developing antibody-based medicines for cancer and autoimmune diseases. The company expects to present XmAb819 clinical results at the ESMO Congress, O

$XNCR is developing antibody-based medicines for cancer and autoimmune diseases. The company expects to present XmAb819 clinical results at the ESMO Congress, October 23 to 27. The bearish swing range is wide: the rebound topped at $30.61, then retraced to $23.36. At $25.60, price is back above the…